Physician profile
Lori Benninghoff
NPI 1386959039
$548.33
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $322.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $152.33 | 2021-2022 | |
| Glaxosmithkline, LLC. | $113.79 | 2021-2022 | |
| Neurelis, INC. | $87.85 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $83.57 | 2022 | |
| Sobi, INC | $42.43 | 2022 | |
| Ironshore Pharmaceuticals INC. | $22.74 | 2021 | |
| Pfizer INC. | $22.34 | 2021 | |
| Sanofi Pasteur INC. | $16.35 | 2021 | |
| Genentech USA, INC. | $6.93 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Benninghoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.